Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For manufacturers of electronic medical devices, compliance with the EU's Waste Electrical and Electronic Equipment (WEEE) Directive and national Extended Producer Responsibility (EPR) laws is a criti...
Given the evolving landscape of biocompatibility standards, including the anticipated updates to ISO 10993-1, how can medical device manufacturers develop a robust strategy for selecting a qualified c...
As the UK continues to refine its post-Brexit medical device regulatory framework, how should manufacturers not established in the UK strategically prepare for the evolving role and responsibilities o...
Given the increasing enforcement actions by Data Protection Authorities (DPAs) and an evolving legal landscape expected to mature by 2026, how should a non-EU organization, particularly one processing...
With significant revisions to the ISO 10993-1 standard anticipated around 2026, how can medical device manufacturers effectively evaluate a biocompatibility testing laboratory's readiness for these ch...
As the UK's future medical device regulatory framework evolves, what are the key practical changes and heightened responsibilities manufacturers should anticipate for their UK Responsible Person (UKRP...
Beyond simply appointing a legal entity within the Union, what specific, multi-faceted criteria should a non-EU cosmetics brand use to vet and select a qualified EU Responsible Person (RP) in preparat...
As regulators worldwide intensify their focus on data integrity and security, how should a manufacturer planning for a 2026 submission for a connected medical device, such as a Software as a Medical D...
For non-EU medical device manufacturers planning for EU market access and compliance through 2026, selecting an EU Authorized Representative (AR) is a critical strategic decision, not merely an admini...
When planning for UK market access, particularly with potential regulatory updates on the horizon, how can medical device manufacturers effectively budget for a UK Responsible Person (UKRP) service? B...
For non-EU manufacturers placing regulated products on the European market, selecting an in-country representative is a critical compliance step. What key criteria should a manufacturer evaluate when ...
For a U.S.-based Software as a Medical Device (SaMD) company marketing its product in the European Union, navigating the regulatory landscape involves more than just CE marking under the EU MDR. When ...
Given the significant legal responsibilities assigned to the EU Authorized Representative (AR) under the Medical Device Regulation (MDR), how should a non-EU manufacturer structure a robust due dilige...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must designate a U.S. Agent. Beyond the fundamental requirement of providing a physical U....
For a non-EU medical device manufacturer, what key criteria and due diligence steps are essential when selecting and qualifying an EU Authorised Representative (AR) under the Medical Device Regulation...
For a U.S.-based manufacturer of a Class II Software as a Medical Device (SaMD) that processes personal health data from EU and UK users, navigating market entry involves appointing representatives fo...
As the Carbon Border Adjustment Mechanism (CBAM) enters its definitive phase in 2026, non-EU businesses importing covered goods into the EU will need representation to manage their compliance obligati...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), how can a foreign cosmetic manufacturer establish a robust vetting process to select the most effective FDA U.S. Agent...
As medical device manufacturers plan their long-term compliance strategies under the EU MDR, particularly with transitional deadlines approaching, how should they strategically evaluate and select an ...
For a sponsor preparing a 510(k) submission for a Class II Software as a Medical Device (SaMD) that processes and transmits patient data, what are the essential components of the cybersecurity documen...